Old Drug Verapamil May Have New Use in Type 1 Diabetes

In randomized trial, the old cardiac agent slowed the destruction of insulin-producing beta cells in youth with new-onset type 1 diabetes.

Related Keywords

Colorado ,United States ,Germany ,Hanover ,Niedersachsen ,Australia ,University Of Adelaide ,South Australia ,Auf Der Bult ,Jennifer Couper ,Gregoryp Forlenza ,Torben Biester ,Provention Bio ,Ypsomed Holding ,Ascensia Diabetes Care Holdings ,Astrazeneca ,Barbara Davis Center ,University Of Colorado ,Medtronic ,Novo Nordisk ,Advanced Technologies ,Anschutz Medical Campus ,Hybrid Closed Loop Therapy ,Beta Cell Preservation ,New Onset Type ,Drug Administration ,Bult Zentrum Diabetes Center ,More Work Needed ,C Peptide Effect ,Tight Glycemic Control ,Tandem Diabetes Care ,Beta Bionics ,European Commission Expert Panel ,Medical Devices ,Diabetes Mellitus Type 1 ,Iabetes Mellitus Type I ,Type 1 Diabetes ,Children ,Child ,Childhood ,Ediatrics ,Kids ,Monoclonal Antibody ,Etuximab ,Ituximab ,Adolescent Medicine ,Endocrinology ,Ndocrine System ,Calcium Channel Blockers ,Insulin Pump ,Continuous Subcutaneous Insulin Infusion ,Pancreas ,Hypertension ,